Seeking Alpha

The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The...

The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The approval triggers a $10.5M milestone payment to ImmunoGen, with royalties from sales to follow. Shares are halted. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs